[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma-eye\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma-eye":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100616257","quality-of-life-after-glaucoma-surgery-evaluating-the-patient-perspective-across-surgical-options-100616257",false,"NCT07303257","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options","Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options - G-SCOPE (Glaucoma Surgery - Comparative Patient Evaluation)","G-SCOPE","Inclusion Criteria:\n\n* Patient aged ≥ 18 years with an indication for glaucoma surgical treatment\n* Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C\n* Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages\n* Pseudoxexfoliative or pigmentary glaucoma\n* Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma\n* Written informed consent obtained prior to study participation\n\nExclusion Criteria:\n\n* Congenital glaucoma\n* Refractory glaucoma with a history of multiple previous surgeries\n* Ophthalmologic surgery within 6 months prior to inclusion\n* Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions)\n* Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period\n* Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study\n* Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder.\n* Patients under curatorship or guardianship\n* Pregnant women","ALL","18 Years",{"count":20,"type":21},132,"ESTIMATED","OBSERVATIONAL","Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments.\n\nHowever, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques.\n\nFurthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being.\n\nThis study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery.\n\nThe study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.",[25,26,27,28,29],"Glaucoma Eye","Open-angle Glaucoma","Closed-Angle Glaucoma","Pseudo Exfoliative Syndrome","Pigmentary Glaucoma",[31,32,33,34,35,36,37,38],"Glaucoma","Trabeculectomy","Sclerectomy","PreserFlo® Micro Shunt","Quality of life","Glaucome Surgery","MIGS","NEI-VFQ 25 (National Eye Institute- Visual Function Questionnaire 25)","RECRUITING","2026-03-12",{"date":42,"type":43},"2026-03-16","ACTUAL",{"date":45,"type":43},"2026-02-23",{"date":47,"type":21},"2027-08",{"name":49,"class":50},"Hospices Civils de Lyon","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100562787","changes-in-eye-pressure-in-glaucoma-patients-treated-with-istent-inject-w-monitored-by-a-contact-lens-sensor-100562787","NCT06607705","Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor","Fluctuations of the Intraocular Pressure in Surgically Treated Glaucoma Patients with IStent Inject W by a Contact Lens Sensor","Inclusion Criteria:\n\n* Adult Patients (over 18 years old) with an initial diagnosis of POAG requiring an indication from the patient chart of an untreated IOP of over 21 mm Hg. Diagnosis of NTG requiring an untreated mean diurnal IOP of over 21 mm Hg from diagnosis to enrollment, indicated by the patient chart. Ocular hypertension is defined as a condition in which the IOP was greater than 21 mm Hg in the absence of glaucomatous defects in visual field testing, the normal appearance of the optic disc and nerve fiber layer, anatomic normality, open angles in gonioscopy, and the absence of ocular conditions contributing to the elevation of pressure, such as narrow angles, neovascular conditions, and uveitis.\n* Adult Patients (over 18 years old ) diagnosed with POAG and NTG are defined as those with open normal appearing angles, typical glaucomatous optic atrophy (i.e., neural rim thinning, notching, saucerization, or nerve fiber layer disc haemorrhage), and typical glaucomatous visual field damage (i.e., arcuate, paracentral scotoma, or nasal step).\n* Adult Patients (age over 18 years old ):\n\nwith unilateral or bilateral open-angle glaucoma (POAG) without previous eye surgery, treated with topical anti-glaucoma medications, who need glaucoma surgery with iStent inject W. The investigators will include patients with isolate iStent surgery and patients with combined cataract and iStent surgery. In cases of bilateral glaucoma, the two eyes of the same patient may be included consecutively.\n\nFor the control group only: Patients with topical hypotensive glaucoma treatment requiring cataract surgery.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Visual defects attributable to nonglaucomatous conditions, primary angle closure glaucoma, neovascular glaucoma, history of ocular trauma, retinal disease or ocular inflammation, and laser therapy or secondary glaucoma.\n* The patients have to meet best-corrected Snellen visual acuity of under 0.3 and spherical equivalent of under 6 diopter.\n* We will not include patients with previous ocular surgery, except cataract surgery performed at least 6 months prior to the inclusion date.",{"count":60,"type":21},53,"INTERVENTIONAL",[63],"NA","The purpose of this study is to compare the IOP-related fluctuations using the CLS (contact lens sensor) Sensimed Triggerfish in glaucoma patients before and after glaucoma surgery with iStent inject W under physiological conditions and compare these results with a control group of glaucoma patients treated only with hypotensive medical treatment requiring cataract surgery.",[25],[67,68,69,70,71,72,73,74],"intraocular pressure (IOP)","glaucoma","cataract","ophthalmology","Contact Lens Sensor (CLS)","Glaucoma surgery","iStent inject W","Sensimed Triggerfish","2025-03-04",{"date":77,"type":43},"2025-03-06",{"date":79,"type":43},"2024-10-21",{"date":81,"type":21},"2025-10-01",{"name":83,"class":50},"Fundacio Privada Mon Clinic Barcelona",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100491926","tied-tube-trial-in-glaucoma-surgery-100491926","NCT05685485","Tied Tube Trial in Glaucoma Surgery","The Effects of Temporary Tube Ligation in Ahmed Glaucoma Valve Surgery","Inclusion Criteria:\n\n* Subjects with age at screening ≥ 18 years\n* Inadequately controlled glaucoma or ocular hypertension\n* Ahmed valve implant as the planned surgical procedure\n* Patients with primary glaucomas (Primary Open Angle Glaucoma or Primary Angle Closure Glaucoma) or pseudoexfoliation, pigmentary and traumatic glaucoma with or without a previous failed trabeculectomy or other intraocular surgery.\n* Primary tubes included\n* Investigators to recruit consecutively all eligible patients from their clinics.\n* Capable and willing to provide consent\n\nExclusion Criteria:\n\n* Subjects with NLP vision\n* Subjects unable\u002Funwilling to provide informed consent\n* Unavailable for regular follow up\n* Previous cyclodestructive procedure\n* Prior scleral buckling procedure or other external impediment to drainage device implantation\n* Presence of silicone oil\n* Vitreous in the anterior chamber sufficient to require a vitrectomy\n* Uveitic glaucoma\n* Neovascular glaucoma\n* Nanophthalmos\n* Patients with pathology that may cause elevated episcleral venous pressure\n* Procedure combined with ocular surgery other than cataract surgery (i.e. combined tube-cataract surgery is okay)\n* Any abnormality other than glaucoma in the study eye that could affect tonometry.",{"count":93,"type":21},152,"The aim of this study is to assess whether delaying early flow through the Ahmed tube shunt may improve the post-operative surgical outcomes and provide a more predictable outcome. To assess this the investigator will conduct a, randomized prospective, multi-centered study with collaborators at WashU in St. Louis, Duke University, Indiana University and the University of Pittsburgh. Participants will be randomized to have an AGV placement with tube ligation (no-early flow) and without ligation (allowing for early flow). IOP will be measured at day one, week one, and months, one, three six, and twelve. Additionally, clinical data regarding number of glaucoma medications, and complications post-operative complications will also be collected.",[25,96],"Ahmed Glaucoma Valve Implantation","2024-08-26",{"date":99,"type":43},"2024-08-27",{"date":101,"type":43},"2022-10-18",{"date":103,"type":21},"2025-01-31",{"name":105,"class":50},"Washington University School of Medicine"]